Drugs Containing Excipient (Inactive Ingredient) METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER

Branded drugs containing METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Wyeth Pharmaceuticals LLC a subsidiary of Pfizer Inc	PROTONIX	pantoprazole sodium	0008-0843	METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER
Allergan Inc	ASACOL HD	mesalamine	0023-5901	METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER
Sanofi-Aventis US LLC	FLOMAX	tamsulosin hydrochloride	0024-5837	METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER

Generic drugs containing METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER excipient

Company	Ingredient	NDC	Excipient
Wyeth Pharmaceuticals LLC a subsidiary of Pfizer Inc	pantoprazole sodium	0008-0843	METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER
Allergan Inc	mesalamine	0023-5901	METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER
Sanofi-Aventis US LLC	tamsulosin hydrochloride	0024-5837	METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER

Methacrylic Acid and Ethyl Acrylate Copolymer Market Dynamics and Financial Trajectory

Last updated: August 17, 2026

Methacrylic acid and ethyl acrylate copolymer is a specialty pharmaceutical excipient used primarily for enteric and delayed-release coatings. Its commercial market is concentrated among a small number of qualified suppliers, with demand tied to oral solid-dose manufacturing, pH-dependent drug release, generic reformulation, and outsourcing of coating operations. The market has attractive technical barriers but limited public financial transparency because suppliers generally report it within broader pharmaceutical excipient or coating portfolios.

The strongest commercial products include Evonik’s EUDRAGIT L 30 D-55 and L 100-55, BASF’s Kollicoat MAE grades, and coating systems from companies such as Colorcon that use comparable methacrylic acid copolymer technology. Revenue growth is likely to remain moderate, supported by oral dosage volumes and formulation complexity rather than by rapid expansion in total pharmaceutical consumption.

What is methacrylic acid and ethyl acrylate copolymer used for?

Methacrylic acid and ethyl acrylate copolymer is an anionic acrylic polymer used to protect drug products from gastric conditions and release active ingredients in the intestine.

The polymer contains methacrylic acid groups that remain largely insoluble in acidic media but ionize as pH increases. The resulting pH-dependent solubility allows formulators to select release thresholds based on polymer composition and grade.

The principal applications are:

• Enteric film coating of tablets, capsules, and multiparticulates
• Delayed-release pellets and granules
• Taste masking
• Protection of acid-labile active ingredients
• Colon-targeted or site-specific delivery when combined with other polymers
• Modified-release coating systems
• Dry or aqueous coating formulations

The 1:1 methacrylic acid-to-ethyl acrylate copolymer is commonly associated with dissolution beginning near pH 5.5. Product performance depends on polymer grade, neutralization, plasticizer selection, coating weight, curing conditions, and substrate properties.

The excipient does not have pharmacological activity. It is evaluated as part of the finished dosage form rather than approved as an independent drug substance.

Which commercial grades contain methacrylic acid and ethyl acrylate copolymer?

The main commercial grades are sold either as dry powders or aqueous dispersions.

Supplier	Commercial product family	Typical form	Principal use
Evonik	EUDRAGIT L 100-55	Dry powder	Enteric coating and delayed release
Evonik	EUDRAGIT L 30 D-55	Aqueous dispersion	Direct aqueous film coating
BASF	Kollicoat MAE grades	Dry powder or dispersion, depending on grade	Enteric and delayed-release coating
Colorcon	Acryl-EZE and related systems	Ready-to-use coating system	Enteric film coating
Regional and contract suppliers	Equivalent methacrylate copolymers	Powder or dispersion	Generic and local-market formulations

EUDRAGIT L 100-55 and L 30 D-55 are among the most recognizable products in the category. Evonik identifies these grades as methacrylic acid-ethyl acrylate copolymers used for enteric coatings with dissolution at approximately pH 5.5.[1]

Finished coating systems can contain the copolymer plus pigments, plasticizers, anti-tacking agents, suspending agents, and processing aids. These systems compete with the pure excipient on ease of use, process robustness, technical support, and regulatory documentation.

How large is the methacrylic acid and ethyl acrylate copolymer market?

No audited public market size is consistently reported for this specific polymer. Public company filings generally combine it with broader categories such as pharmaceutical polymers, oral drug-delivery excipients, coating systems, or health-care materials.

The market is best characterized as a small specialty segment within the global pharmaceutical excipient industry. Its financial profile differs from high-volume excipients such as lactose, microcrystalline cellulose, starch, and polyvinylpyrrolidone:

Market characteristic	Assessment
Market size	Niche relative to the total pharmaceutical excipient market
Supplier concentration	High
Switching cost	Moderate to high
Unit value	Higher than commodity fillers and binders
Volume growth	Closely linked to oral solid-dose production
Pricing power	Stronger for validated grades and ready-to-use systems
Regulatory burden	Moderate, with substantial customer qualification work
Substitution risk	Moderate
Public revenue disclosure	Very limited

The financial opportunity is concentrated in repeat supply to approved products. Once a polymer grade is embedded in a commercial formulation, changing suppliers may require comparative dissolution, stability, process validation, regulatory review, and sometimes post-approval filings. That creates recurring revenue and reduces short-term price elasticity.

What drives demand for this pharmaceutical excipient?

Demand is driven primarily by oral solid dosage development and manufacturing.

Growth in generic delayed-release products

Generic manufacturers use enteric polymers in products such as proton-pump inhibitors, nonsteroidal anti-inflammatory drugs, enzyme products, and drugs requiring intestinal release. Generic competition can expand unit volumes even when pricing pressure reduces finished-product margins.

Outsourcing and contract manufacturing

Contract development and manufacturing organizations increasingly provide coating, pelletization, and multiparticulate services. These manufacturers purchase validated polymers in recurring volumes and may favor suppliers that provide technical packages, batch documentation, and global regulatory support.

Formulation complexity

Complex oral products require tighter control of dissolution profiles, coating uniformity, curing, and stability. This favors suppliers with established process data and reduces the attractiveness of unqualified low-cost alternatives.

Aqueous processing

Aqueous dispersions can reduce or eliminate the use of organic solvents. Environmental, occupational safety, and plant-permitting considerations support demand for water-based products such as L 30 D-55 and comparable dispersion grades.

Regional pharmaceutical expansion

India, China, Southeast Asia, Latin America, and the Middle East have growing generic and contract manufacturing capacity. Local manufacturers are expanding access to enteric-coated medicines, although purchasing decisions remain sensitive to price and supply continuity.

How does the polymer compare with competing enteric excipients?

Methacrylic acid and ethyl acrylate copolymer competes with cellulose-based polymers, polyvinyl acetate phthalate, and other methacrylate copolymers.

Excipient	Typical release behavior	Main advantages	Main limitations
Methacrylic acid-ethyl acrylate copolymer	Approximately pH 5.5 for 1:1 grades	Strong enteric performance, aqueous dispersion availability	Requires formulation and curing control
Methacrylic acid-methyl methacrylate copolymer	Often pH 6.0 or higher, depending on grade	Higher-pH intestinal release options	May require different coating conditions
HPMCP	Grade-dependent	Established cellulose technology	Solvent and film-performance considerations
HPMCAS	pH-dependent intestinal release	Strong amorphous-solid-dispersion platform	Higher cost and different processing requirements
Polyvinyl acetate phthalate	Enteric release	Established dry coating use	Lower market momentum in some applications
Cellulose acetate phthalate	Enteric release	Long history of use	Moisture and film-performance limitations

HPMCAS is a more significant competitor in amorphous solid dispersions, while methacrylate copolymers remain strongly positioned in conventional enteric coatings and multiparticulate systems.

What is the regulatory status of methacrylic acid and ethyl acrylate copolymer?

Methacrylic acid and ethyl acrylate copolymer is regulated as a pharmaceutical excipient within the context of finished drug products. It is not an FDA-approved active pharmaceutical ingredient.

Relevant regulatory considerations include:

• Inclusion in recognized pharmacopeial specifications, including USP-NF and European Pharmacopoeia frameworks
• Review through the FDA Inactive Ingredient Database where applicable
• Supplier documentation covering residual monomers, heavy metals, microbial quality, particle size, viscosity, and residual solvents
• Product-specific assessment of coating level and route of administration
• Regional requirements for excipient quality, manufacturing controls, and change notification

The FDA Inactive Ingredient Database is a key reference for determining prior use in approved drug products and identifying route- and dosage-form-specific precedent.[2] The database does not create an independent approval or market exclusivity right for the excipient.

European regulators evaluate excipient quality and suitability through finished-product applications, quality documentation, and risk-based assessment. The European Medicines Agency has issued guidance addressing excipient selection and pharmaceutical development considerations.[3]

What patents protect methacrylic acid and ethyl acrylate copolymer products?

The base polymer is a mature technology. Core composition patents associated with widely used methacrylate copolymers are generally old and do not provide a modern, composition-level exclusivity barrier equivalent to a new drug patent.

The more relevant forms of protection are:

• Manufacturing process know-how
• Polymerization control and residual-monomer reduction
• Particle-size and dispersion control
• Spray-drying and powder-processing methods
• Coating formulations containing the polymer
• Specific plasticizer and neutralization systems
• Drug-polymer combinations
• Multiparticulate dosage forms
• Manufacturing equipment and process parameters
• Trademarks such as EUDRAGIT

Patent risk therefore depends on the specific finished formulation or manufacturing process, not merely on use of the copolymer itself.

Are Orange Book listings and Paragraph IV challenges relevant?

No. The polymer is an excipient and is not independently listed as an active drug product in the FDA Orange Book. It does not have standalone Hatch-Waxman exclusivity, a patent-term extension, or a Paragraph IV challenge pathway.

Paragraph IV disputes may arise for a finished drug product that uses the polymer, but those disputes concern the active ingredient, dosage form, method of treatment, formulation, or manufacturing process of the drug product. They do not normally create a patent challenge against the excipient itself.

Is biosimilar risk relevant?

Biosimilar risk is not directly relevant. Methacrylic acid and ethyl acrylate copolymer is used mainly in small-molecule oral dosage forms and is not a biologic active ingredient. It can be used in some specialized delivery systems, but biosimilar interchangeability does not govern the excipient market.

How strong is the supplier patent and manufacturing position?

Supplier positions are stronger in manufacturing and quality systems than in basic polymer composition patents.

A qualified supplier typically has advantages in:

1. Consistent molecular-weight distribution
2. Controlled particle morphology
3. Low residual monomer content
4. Stable aqueous dispersion performance
5. Global regulatory files
6. Technical support for coating equipment
7. Established change-control procedures
8. Multi-site or regional supply capability

These capabilities raise switching costs. A purchaser may be able to buy a chemically similar polymer, but the replacement must reproduce dissolution, mechanical strength, stability, process yield, and release specifications.

The most defensible commercial position is therefore based on a combination of brand recognition, regulatory history, process data, customer qualification, and supply reliability.

Which companies are competing in this market?

Evonik is a leading branded supplier through the EUDRAGIT portfolio. BASF is a major competitor through Kollicoat products and broader pharmaceutical excipient capabilities. Colorcon competes primarily through formulated coating systems and technical service rather than only through sale of the unformulated polymer.

Competitive differentiation is based on:

• Global manufacturing footprint
• Pharmaceutical-grade quality systems
• Aqueous dispersion technology
• Regulatory support
• Availability of small development quantities
• Scale-up assistance
• Regional inventory
• Pricing and contract terms
• Ability to support multiple coating platforms

Regional producers can compete on price, local delivery, and shorter procurement cycles. They face a greater burden when customers require extensive historical data, global filings, or supply from multiple regulated markets.

What is the financial trajectory for this excipient?

The likely financial trajectory is steady specialty-material growth rather than explosive expansion.

Near-term trajectory

Demand should remain supported by generic oral medicines, enteric-coated products, and contract manufacturing. Input-cost volatility can affect pricing through acrylic monomers, energy, packaging, freight, and quality-control expenses. Suppliers with aqueous dispersion capacity and local inventory can defend margins better than undifferentiated distributors.

Medium-term trajectory

Growth should come from:

• Expansion of delayed-release generic products
• More multiparticulate and pellet-based dosage forms
• Increased use of aqueous coating
• Outsourced pharmaceutical manufacturing
• Regionalization of supply chains
• New oral delivery systems requiring pH-triggered release

Margin pressure may increase as regional manufacturers qualify alternatives and pharmaceutical customers consolidate procurement.

Long-term trajectory

Long-term demand is likely to remain durable but constrained by competition from HPMCAS, HPMCP, polyvinyl acetate phthalate, and new functional excipients. The polymer should retain a strong position where formulators value predictable enteric performance and established regulatory precedent.

The highest-value growth is likely to come from formulated coating systems, technical services, and application-specific grades rather than from commodity sales of the base polymer.

What revenue exposure do suppliers have?

Public filings generally do not disclose revenue from methacrylic acid and ethyl acrylate copolymer separately. Revenue exposure must therefore be assessed through portfolio and end-market indicators.

Revenue factor	Impact on suppliers
Exposure to oral solid-dose products	Positive and recurring
Exposure to generic manufacturers	Volume-supportive but price-sensitive
Exposure to major innovator products	Higher margins but lower volume concentration
Ready-to-use coating systems	Positive margin mix
Commodity polymer sales	Greater price competition
Regulatory qualification base	Supports customer retention
Single-site manufacturing	Increases supply-chain risk
Regional inventory	Supports service levels and customer conversion

Supplier earnings can be more resilient than polymer volumes because qualified grades and coating systems often carry technical-service premiums. The principal downside is customer concentration among large generic manufacturers and contract manufacturers.

What licensing and partnership arrangements matter?

Licensing is less important than in active pharmaceutical ingredients. The commercial model is usually based on direct supply, distribution agreements, technical support, and customer qualification.

Relevant partnership structures include:

• Regional distribution agreements
• Contract manufacturing supply arrangements
• Co-development of coating systems
• Technical service agreements with drug manufacturers
• Dual-sourcing qualification programs
• Long-term supply contracts for commercial products

A supplier’s technology may be incorporated into a customer’s formulation without a conventional patent license. The economic value comes from supply continuity, documentation, and process support.

What generic launch risks exist for products using this excipient?

Generic launch risk is usually not driven by access to the polymer. The polymer is commercially available from multiple suppliers. The higher risks are formulation and regulatory risks:

• Failure to match the reference product’s dissolution profile
• Inadequate acid resistance
• Premature release at low intestinal pH
• Coating defects and batch variability
• Stability failure caused by moisture or plasticizer migration
• Incompatibility with the active ingredient
• Need for reformulation after supplier changes
• Delayed regulatory acceptance of an alternate grade

For approved products, the polymer may be replaceable, but the replacement must be demonstrated to produce equivalent finished-product performance.

What geographic coverage does the market have?

The market is global, with production and demand concentrated in North America, Europe, India, China, and other Asian pharmaceutical manufacturing centers.

Europe has a strong supplier base and long regulatory experience with methacrylate polymers. India is a major demand center because of its generic and contract manufacturing industries. China has expanding pharmaceutical production and domestic excipient capacity. North America remains important for innovator development, generic commercialization, and high documentation standards.

Geographic risk is linked to:

• Concentration of polymer production
• Transport of aqueous dispersions
• Import controls
• Regional excipient registration requirements
• Exchange-rate movements
• Local inventory availability
• Qualification of alternate manufacturing sites

Aqueous dispersions are more sensitive to transport and storage conditions than dry powders. This can favor regional warehouses and local technical support.

Key Takeaways

• Methacrylic acid and ethyl acrylate copolymer is a specialty enteric excipient used mainly in delayed-release oral dosage forms.
• The market is concentrated among qualified suppliers, led by Evonik, BASF, and coating-system providers such as Colorcon.
• Public companies do not generally report standalone revenue for this polymer, so market size and supplier exposure must be assessed through broader excipient disclosures.
• Core polymer composition protection is mature. Current competitive advantages arise from manufacturing know-how, quality systems, trademarks, coating formulations, and customer qualification.
• Orange Book listings, Paragraph IV challenges, biosimilar exclusivity, and standalone FDA drug exclusivity do not apply to the excipient.
• Demand should grow steadily with generic oral drugs, multiparticulates, contract manufacturing, and aqueous coating technology.
• The primary risks are substitution, regional price competition, supply concentration, and formulation failure after grade or supplier changes.
• Higher margins are likely in ready-to-use coating systems and technical services rather than in undifferentiated polymer sales.

FAQs

Is methacrylic acid and ethyl acrylate copolymer the same as EUDRAGIT L 30 D-55?

EUDRAGIT L 30 D-55 is a branded aqueous dispersion based on methacrylic acid and ethyl acrylate copolymer. It is not identical to every product sold under the generic excipient name because solids content, particle characteristics, specifications, and manufacturing controls can differ.

Does the polymer dissolve in the stomach?

It is designed to resist dissolution under acidic gastric conditions. The polymer becomes soluble as pH rises, enabling release in the intestine. Actual performance depends on coating thickness, formulation, curing, and the finished dosage form.

Can a pharmaceutical company substitute BASF Kollicoat for EUDRAGIT?

Potentially, but substitution requires technical qualification. The manufacturer must compare polymer specifications, coating process behavior, dissolution, stability, and finished-product performance. Regulatory notification or approval may also be required.

Is methacrylic acid and ethyl acrylate copolymer suitable for capsules?

Yes. It can be used in enteric-coated hard capsules, soft-gel-related systems, pellets, granules, and multiparticulate dosage forms, subject to formulation and process validation.

What is the main investment risk in this excipient market?

The main risk is limited market transparency combined with supplier concentration. Investors and commercial partners may be unable to isolate revenue, margins, or growth for this individual polymer from broader pharmaceutical excipient portfolios.

References

1. Evonik Industries AG. (n.d.). EUDRAGIT L 30 D-55 and EUDRAGIT L 100-55: Product information and pharmaceutical application data. Evonik.

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA. https://www.accessdata.fda.gov/scripts/sda/sdNavigat ion.cfm?sd=inactiveingredient

3. European Medicines Agency. (2016). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. EMA.

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Methacrylic acid and ethyl acrylate copolymer monograph. USP.

5. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia: Methacrylic acid-ethyl acrylate copolymer monograph. EDQM.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files